FLASCO Board Member Discusses Evolving Treatment Options for Patients With mCRPC

  • FLASCO
  • September 16, 2016

 

Richard M. Levine, MD, FLASCO Board Member and Past President, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer (mCRPC). See the video

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO